SPARC announces consolidation of R&D laboratories and facilities

As part of the Company's strategic growth plan, the Company has decided to consolidate its R&D infrastructure and laboratories from multiple sites in Mumbai and Baroda to two sites in Baroda.

This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations, enhancing operational efficiencies and reducing cycle times.

The R&D operations being conducted at Mahakali site in Mumbai and Makarpura site in Baroda will be integrated into the Company's Savli and Tandalja sites in Baroda. As part of the overall cost optimization effort, the Company will outsource some of the R&D activities to third party partners on an as needed basis. The consolidation of laboratory operations and the increased outsourcing could result in excess capacity in certain functions, which the Company aims to streamline by the end of FY26.

The Company's corporate functions will continue to operate out of Mahakali office in Mumbai.

Shares of Sun Pharma Advanced Research Company Limited was last trading in BSE at Rs. 131.10 as compared to the previous close of Rs. 133.15. The total number of shares traded during the day was 10475 in over 290 trades.

The stock hit an intraday high of Rs. 133.15 and intraday low of 130.80. The net turnover during the day was Rs. 1380719.00.

Source : Equity Bulls

Keywords

SunPharmaAdvancedResearchCompany INE232I01014 SPARC Pharmaceuticals Consolidation RandD Laboratories